National High-level Talent Program Expert, National “New Drug Innovation” committee member, recipient of the State Council’s allowance. Doctor of Medicine (M.D.) from the University of Arkansas (U.S.), U.S.-certified pathologist. The 12^th and 13^th National People's Congress member, Standing Committee member and the Deputy Director of the Special Committee on Biological and Medical Special Committees of China Federation of Returned Overseas Chinese, Vice Chairman of Zhejiang Overseas Chinese Federation, Director of the Central Economic and Financial Committee of the Agricultural and Labor Party, Deputy Chairman of the Zhejiang Provincial Committee, Vice President of China Pharmaceutical Promotion Association, President of Zhejiang Pharmaceutical Industry Association. In 2003, Dr. Ding founded Betta Pharmaceuticals Co., Ltd., and led the team to successfully develop China's first small-molecule anti-cancer targeted therapy——icotinib, building a leading R&D and commercialization platform for anti-cancer targeted therapies. He has presided 13 national-level major science and technology projects such as the “New Drug Innovation”, applied for 84 patents, and published 29 articles. Because of his outstanding contributions, Dr. Ding has won National Science and Technology Progress Award (the first accomplisher), Gold Prize of China Patent Award, National Innovation Award, China Industrial Award, National Outstanding Professional and Technical Personnel, National Outstanding Science and Technology Workers, "Top 10" of Overseas Chinese, Zhejiang Province Science and Technology Major Contribution Award and other honors.

Hong Kong University of Science and Technology Executive MBA. He has worked in the orthopedics division at Beijing Tongren Hospital and has held senior management positions in multiple medical institutions and leading pharmaceutical companies, such as Bristol-Myers Squibb, Sanofi-Aventis, Eli Lilly, AstraZeneca, and MSD. With nearly 30 years’ experience in establishing drug promotion channels and improving drug accessibility, he has a significant impact on promoting anti-cancer drugs and the commercialization of drugs in the Chinese market. Mr. Wan is now in charge of the oncology affairs department, the marketing department, and the market access department in Betta.

National High-level Talent Program Expert, Ph.D. in Organic Chemistry, University of Wisconsin. Dr. Wang served in the R&D teams of MSD and AstraZeneca, and has engaged in drug discovery and management for 20 years, leading over 10 drug discovery projects. He has successfully advanced multiple projects into clinical development stage, is the key inventor of numerous new molecules. He has publications and patents totaling 168 and is recognized as an innovative team leader with great achievements in the field of small molecule targeted drug design. Dr. Wang is the head of Betta’s New Drug R&D center.

Graduated from China Pharmaceutical University, Senior Engineer, Medical Practitioner. He has more than 30 years’ experience in manufacturing and quality control at pharmaceutical companies, and has strong capacities in project planning, organizing, and team-building. He is a core member of the First-Class National Scientific and Technological Progress Award （Icotinib hydrochloride Industrialization Project）, a senior member of Zhejiang Province Science and Technology Expert Consortium. He has presided or participated in 2 national-level major science and technology projects in new drug innovation and commercialization, been awarded Zhejiang Provincial Science and Technology Development Outstanding Achievement Award.Mr. Cai is in charge of the manufacturing department and Betta Pharmaceutical (Shengzhou) Co., Ltd.

MBA in Zhejiang University. She joined Betta in 2003 and has served as department manager, director, executive secretary, and VP. With rich experience in corporate operations management, particularly in capital market brand building, she was awarded "Golden Secretary" from a public company by Sina Finance, Outstanding Secretary of China's GEM-listed companies, the Best Secretary of the 2017 Golden Bull and Outstanding Secretary of Zhejiang public companies in 2018. Ms. Tong is in charge of the administrative department, the human resources department, the engineering department, the investor relations department, the public relations department，and assist in the chairman’office. 

MBA from Macau University of Science and Technology. He has served as the president of China Construction Bank Yuhang branch, China Construction Bank Xiaoshan branch, and Shanghai Pudong Development Bank Yuhang branch. With more than 20 years of operation and management experiences in the financial industry, he has amassed strong communication, coordination, and team management skills. He has led or participated in multiple high-quality equity investments and M&A projects. Mr. Fan is in charge of the finance and investment departments.

      Graduated from Bethune Medical University. He has worked for the Institute of Hematology, Chinese Medical College, and held management positions in multinational pharmaceutical companies’ China division such as Roche and Pfizer. With nearly 15 years of team management experience, she has amassed excellent skills in communication, coordination, resource integration and drug brand promotion. She has an in-depth understanding and knowledge of promoting international and domestic anti-tumor drugs, especially for innovative drugs in China. Ms. Shi is in charge of oncology business department.

Dr. Lily Li is Vice President of Strategic Collaboration at Betta Pharmaceuticals. In this role, she leads the effort of expanding the company's innovative pipeline through in-licensing, co-development and strategic investment. Lily has 15 years of experience in drug development, business development and alliance management. Prior to joining Betta, Lily worked at the world-class large pharma -  Merck and AstraZeneca. She was appointed as Director of Strategic Collaboration at Betta in 2017. Since joining Betta, Lily has led the BD team establishing strategic partnerships with over 10 global and domestic companies, 3 of these programs are currently under registration studies and expected to be launched before 2022. Lily received her Bachelor of Science degree from Peking University, China and her Ph.D. in Chemistry from Washington University in St. Louis, U.S.. She was elected in Zhejiang Recruitment Program of Global Expert in 2018.

Graduated from China Pharmaceutical University. He has served for Zhejiang Medical Products Administration and has been working in drug registration and quality management for many years. With more than 20 years’ experience in quality management, GMP certification and registration affairs in the pharmaceutical industry, he has excellent capacities in project management, guideline setting, and team management. He has presided or participated in 2 national-level major science and technology projects in new drug innovation and commercialization. Mr. Ma is in charge of the quality management department, registration affairs department.

Graduated from Beijing University of Chinese Medicine. He has worked for multinational pharmaceutical companies such as Kirin Group, Sanofi-Aventis, and AstraZeneca. With more than 20 years of pharmaceutical sales experience and more than 10 years of business management experience, he has excellent communication, coordination and team management skills. Mr. Liu is in charge of the business and market access departments.

As a graduate of Peking University, Dr. Liu obtained his Ph.D. degree from Emory University, majoring in Organic Chemistry. He has over 20 years of experience in the pharmaceutical industry and the FDA.He held senior management positions in leading pharmaceutical companies, such as Johnson & Johnson, FDA, evinus pharmaceutical, Inc., GlaxoSmithKline, and Xiansheng pharmaceutical. He has a lot of experience in R&D management, team management, project management, CRO management, etc. He also has experience in the review of many NDAs and INDs at the FDA along with IND submission at the pharmaceutical industry. During his four-year tenure at the FDA as a CMC reviewer, he participated in the review and approval of many INDs and blockbuster NDAs, including the first FDA approved 4-in-1 fixed-dose combination (FDC) drug of Stribild for HIV treatment and the milestone HCV drug of Sovaldi from Gilead Sciences. Dr. Liu is in charge of CMC.

Zhejiang Provincial High-level Talent Program Expert, Bachelor of Biochemistry, Fudan University, Ph.D. in Genetics from the Chinese Academy of Sciences, postdoctoral research in genetics, cancer and diabetes at the University of Leicester and the University of Wisconsin. He has conducted drug discovery research at multinational pharmaceutical companies such as Schering-Plough, MSD, and Eli Lilly, and has led multiple drug discovery projects. He has more than 20 years of academic research and drug discovery experience in the field of diabetes and cancer, and has published more than 50 papers, including more than 20 papers as the first author or corresponding author. With strong organizational, leadership and management capabilities, he is leading multiple pharmaceutical R&D projects in Zhejiang Province. Dr.Lan is in charge of new drug discovery and pharmacology, meanwhile assists on overseas strategic business development activities.

MBA from Peking University.He has held senior management positions in pharmaceutical companies such as Xian Janssen, Novartis China, and Hengrui Medicine.He has worked in the field of clinical medicine for more than 30 years ,with rich experience in the clinical management and medical team building.Mr. Ji is in charge of clinical operation and medical affairs.

       Graduated from Anhui Medical University. He has worked at Anhui Provincial Children's Hospital, and held senior positions in the sales department of multinational pharmaceutical companies’ China division such as Roche. He has more than 20 years of sales experience in pharmaceutical companies, including 15 years’ experience in anti-tumor drugs sales for multinational pharmaceutical enterprises. He has outstanding team building and resource coordination capabilities, with a comprehensive understanding and knowledge of international and domestic pharmaceutical markets. Mr. Mao assists in charge of oncology business department.

Ph.D. in Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Science. He has worked in well-known research institutes such as Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Chinese Academy of Sciences, and pharmaceutical companies such as WuXi AppTec. He has over 18 years’ experience in organic synthesis, process development, new drug design and development, and has participated in over 60 projects, many of which has been progressed to the clinical development stage. He has obtained more than 70 international and domestic patents and is the inventor of anti-HBV drug TQ-A3334 and HCV drug elbasvir. With excellent project management, team management and system building capabilities, Dr. Wu is in charge of Hangzhou R & D center.

M.A. of Applied Biology and Ph.D. in Biofunction, National Shinshu University, Japan. He has worked in well-known biotech companies such as Metabolon and NantWorks and participated in the U.S. Cancer Moonshot 2020 project. He has worked in the field of life science research for more than 20 years, with rich experience in the design, testing, production, development of tumor biological models, and clinical research of immunology therapies. He has presided and managed multiple R&D projects, and successfully advanced numerous projects into clinical research, acting as a key developer of multiple new therapies. He has published more than 50 papers (including patents), two of which are on the cover of top-tier journals. With outstanding project management and team building capabilities, Dr. Xu is in charge of the department of immunobiology (R&D Center).

Master in Finance from Peking University,Sponsor Representative. Wealth of experience in A-share IPOs and overseas IPOs, equity refinancing, mergers and acquisitions, bond financing and other capital operation. Prior to joining Betta, Mr. Wu has dedicated to investment banking business at GTJA (GUOTAI JUNAN SECURITIES), UBSS (UBS Securities Co. Limited) and HUATAI UNITED SECURITIES. He is in charge of the securities department.

He received the MD degree in University of Torino (Italy) in 1992 and then completed residency in Pulmonology. After 17 years as a clinician and investigator in clinical trials for lung cancer and mesothelioma, joined GSK in 2010 as medical director on a cancer vaccine program. After that he covered leadership positions in Novartis (lead for ceritinib, ALK inhibitor), Oncolytics and Bristol Myers Squibb (nivolumab lead in SCLC and mesothelioma) till 2019 when he joined Xcovery in 2019 as Chief Medical Officer to lead ensartinib and vorolanib clinical programs. From March 2021 he became CEO of Xcovery. He was appointed as Medical Advisor of Betta in May 2021, mainly give advice and joint effort in the area of clinical development of new drugs and international collaboration.

Kevin Ding, Chairman assistant, graduated from St. Louis University and joined Betta Pharmaceuticals in 2018.He has a comprehensive background majoring in both Biochemistry and Economics. Prior to becoming Chairman assistant, he served as a director of strategic collaboration and the executive vice general manager of Betta Dream Works. While holding those titles, Kevin Ding was directly involved with the in-licensing of MCLA-129, Ensartinib, and the promotion of Betta Amgen and other projects. Addition to these accomplishments Mr. Ding has successively reached strategic cooperations with Inventis Bio and Agenus, adding cornerstone assets to Betta’s pipeline. He helped manage the transactions of the investment department, participated in many high-quality equity investment or M & A projects, and led the equity investment in Xcovery. He has rich experience in business cooperation, personnel management and project promotion.